Trump tariffs will challenge the big pharmaceuticals. Here are well positioned actions
Long Data Commercial Agreements have greatly protected the pharmaceutical industry of tariffs, but the objective of President Donald Trump to…
Bristol-Myers Squibb Co.
Do not ignore the impact of pharmaceutical rates, says an analyst. Where we stop in Bristol Myers
The drug stock is higher during the past month, while the S&P 500 has retired sharply.
We are reserving profits in a rally rotation game and buying another 2 on the dip
We are making a handful of more offices on Tuesday. Sell 75 shares of Ge Healthcare to approximately $ 86…
We are adding to our position in a sliding stock and reserve profits in a 2025 winner
We are doing a couple of trades on Monday when Wall Street Rallies to start the week.
Trump could make changes to Medicare drug price negotiations
President Donald Trump arrives at the Brady Press room at the White House on January 30, 2025 in Washington, DC.…
Stocks rise on cold inflation, hot bank profits and new rules on biotech exports to China
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Anti-schizophrenia drug Cobenfy could treat Alzheimer's
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, USA, on Wednesday, December 27, 2023.…
Eli Lilly and Amazon announce agreements at JPMorgan conference
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
FDA approvals fall in 2024, Transcarent acquires Accolade
Signs are seen outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, on August 29, 2020. Andrew…
We're adding to our position in a stock that just got some big support from Wall Street.
Shortly after the bell rings, we will buy 300 shares of Bristol Myers Squibb at approximately $56.50. Following the deal,…